Bio Green Med Solution, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Fire Safety Equipment at $603,000, 81% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2
|
1
|
0
|
0
|
0
|
0
|
—
|
—
|
0
|
0
|
1
|
| Fire Safety Equipment |
—
|
1
share 80.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Safety Aparel |
—
|
0
share 15.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Clinical Trial Supply |
—
|
—
|
0
-89.8%
share 100.0%
|
0
share 100.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Project Supply And Installation |
—
|
0
share 2.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Maintenance And Servicing |
—
|
0
share 0.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Wholesale-Durable Goods, NEC (SIC 5099)
- Listed as
- BGMS (Nasdaq), BGMSP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1130166
- Former names
- Cyclacel Pharmaceuticals, Inc. (until Sep 12, 2025); XCYTE THERAPIES INC (until Mar 24, 2006)
Other Wholesale-Durable Goods, NEC companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.